Murad Hussain is an experienced trial lawyer who represents clients in all stages of criminal prosecutions, government-facing litigation, and related investigations. His practice focuses on defending and counseling life sciences innovators, healthcare providers, government contractors, and others in matters involving the False Claims Act (FCA), criminal fraud laws, the Anti-Kickback Statute (AKS), Medicare regulatory decisions, and the Foreign Agents Registration Act (FARA). He also helps clients use their business data to promote internal compliance and counter the government's use—and misuse—of data analytics and statistics during investigations and trial. Murad has been recognized by The Legal 500 as a “Next Generation Partner” for healthcare and life sciences matters, by DC’s Best Lawyers for white collar criminal defense and FCA qui tam defense, and by DC’s Super Lawyers as a “Rising Star.” He serves on the firm’s Pro Bono Committee, as the partner editor for the firm’s Enforcement Edge blog, and as an Adjunct Professor of trial practice at the Georgetown University Law Center.

Murad is an accomplished advocate for both plaintiffs and defendants facing the U.S. Department of Justice (DOJ). Most recently, he led the team that brought former FBI Deputy Director Andrew McCabe’s wrongful termination suit, defeated the government’s summary judgment motion, and negotiated the settlement restoring Mr. McCabe’s retirement status and benefits, with Attorney General Garland later telling Congress that DOJ settled “because of a likelihood of loss on the merits.” Murad also defended Dr. Salomon Melgen at trial against claims of bribing U.S. Senator Robert Menendez, and successfully argued for acquitting both men of all charges involving First Amendment-protected political contributions—a ruling that, in The New York Times’ words, “blew a hole” in the prosecution’s case and led to the dismissal of all remaining charges.

Murad served as a law clerk to the Honorable Ellen Segal Huvelle of the United States District Court for the District of Columbia. He earned his law degree from Yale Law School, where he received the Potter Stewart Prize for best moot court team and the President’s Public Service Fellowship. Before law school, he worked as a creative executive at a Hollywood studio-based production company.


  • Pharmaceutical innovators, in winning dismissal of two related FCA qui tam suits concerning promotional activities. U.S. ex rel. JKJ Partnership 2011, LLP v. Sanofi Aventis, U.S., LLC, et al., No. 3:11-CV-6476, 2021 WL 5002715 (D.N.J. Oct. 28, 2021); U.S. ex rel. Dickson v. Bristol-Myers Squibb Co., et al., 332 F. Supp. 3d 927 (D.N.J. 2017).
  • National home health care provider, in negotiating a no-fault overpayment settlement with DOJ and securing the dismissal of five FCA qui tam suits concerning laboratory and diagnostic testing.
  • Pharmaceutical innovator, in defending against a corporate relator’s FCA qui tam suit concerning nurse educator and reimbursement services. U.S. ex rel. CIMZNHCA, LLC v. UCB, Inc., 970 F.3d 835 (7th Cir. 2020) (ordering dismissal over relator’s objections).
  • Naval contractors, in defending against the federal government’s FCA suit, arguing for the FCA’s non-extraterritoriality, and securing a no-fault dismissal.
  • Multiple cardiology and vascular surgery practices, in defending against FCA investigations by various U.S. Attorney’s Offices and negotiating no-fault settlements.
  • Federal procurement contractor, in winning dismissal of a FCA qui tam suit alleging violations of the Trade Agreements Act. U.S. ex rel. Berkowitz v. Automation Aids, Inc., No. 13-CV-8185, 2017 WL 1036575 (N.D. Ill. Mar. 16, 2017), aff’d, 896 F.3d 834 (7th Cir. 2018).
  • Radiation oncology practice, in winning dismissal of a FCA qui tam suit alleging violations of Medicare requirements for supervision of medical procedures. U.S. ex rel. Parker v. Space Coast Medical Associates, L.L.P., 94 F. Supp. 3d 1250 (M.D. Fla. 2015).
  • National hospital management company, in federal investigations, proceedings before the Judicial Panel on Multi-District Litigation, and multiple nationwide FCA qui tam suits alleging medically unnecessary procedures and violations of the Stark Law and AKS.


A Low Bar for Dismissal: SCOTUS Gives DOJ Broad Discretion to Seek Dismissal of Qui Tams
Qui Notes: Unlocking the False Claims Act
Things Ain’t What They “Use[d]” to Be: SCOTUS Narrows the Aggravated Identity Theft Statute
Enforcement Edge: Shining Light on Government Enforcement
Ciminelli and Percoco — Federal Public Corruption Prosecutors Suffer Two More Unanimous Losses at the Supreme Court
Enforcement Edge: Shining Light on Government Enforcement
Legal Jeopardy: What Are Our Compliance Risks?
Speaker, Outpatient Endovascular and Interventional Society’s 10th Annual National Scientific Meeting, Lake Buena Vista, FL
Trial Practice Demonstration – United States of America v. Young Yi (E.D. Va.)
Speaker, ABA's 33rd Annual National Institute on Health Care Fraud, Chicago, IL


Best Lawyers
Qui Tam Law (DC) (2021-2024)
Criminal Defense: White Collar (DC) (2023)
The Legal 500 U.S.
"Next Generation Partner" Healthcare: Life Sciences (2020-2023)
Healthcare: Life Sciences (2021-2022)
Healthcare: Service Providers (2021)
Washington, DC Super Lawyers
"Rising Star"Criminal Defense: White Collar; Government Contracts; Health Care; Civil Litigation: Defense (20142017)


  • J.D., Yale Law School
  • A.B., Harvard College, magna cum laude
  • District of Columbia
  • California
  • Virginia
  • U.S. Court of Appeals for the District of Columbia Circuit
  • U.S. Court of Appeals for the Third Circuit
  • U.S. Court of Appeals for the Fourth Circuit
  • U.S. Court of Appeals for the Eleventh Circuit
  • U.S. District Court, District of Columbia
  • U.S. District Court, Central District of California
  • U.S. District Court, Eastern District of Virginia
  • U.S. District Court, District of Columbia, The Honorable Ellen Segal Huvelle

Email Disclaimer